Why Farbe Firma is the Top Manufacturer of Orphenadrine Citrate Injection
- Maulik Sudani
- 1 day ago
- 8 min read
Last Updated: June 24, 2026
TL;DR: Orphenadrine Citrate Injection — a sterile, clear, colourless aqueous solution of orphenadrine citrate, a centrally acting muscle relaxant with anticholinergic and antihistaminic properties that relaxes skeletal muscle and relieves the pain of acute muscle spasm, supplied commonly as a 30 mg/mL solution (for example 60 mg in 2 mL) given by intramuscular or intravenous injection — is a widely used medicine for the short-term relief of pain from acute musculoskeletal conditions, used as an adjunct to rest and physical therapy. Because the active is delivered parenterally and orphenadrine carries a meaningful anticholinergic action, each ampoule or vial must deliver an exact, sterile, particulate-free dose at the labelled strength, with the stability-indicating assay, the related-substance profile, solution pH, fill volume, low particulate and endotoxin, antioxidant protection where used, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Orphenadrine Citrate Injection at our Gujarat, India facility and supplies it to orthopaedic, emergency, rehabilitation and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Centrally acting muscle relaxant with anticholinergic and antihistaminic activity — orphenadrine relaxes skeletal muscle and relieves the pain of acute spasm, and Orphenadrine Citrate Injection (30 mg/mL, intramuscular or intravenous) gives rapid short-term relief in acute musculoskeletal conditions, where an exact, reproducible parenteral dose is essential.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated compounding and ampoule and vial filling lines, control of the stability-indicating assay, the related-substance profile, solution pH, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Orphenadrine Citrate Injection Demands a Premium Manufacturer
Orphenadrine Citrate Injection holds a practical, everyday place in emergency departments, orthopaedic and trauma wards, rehabilitation units and pain services across many markets. It is the muscle relaxant that clinicians reach for when a patient arrives with the sharp, disabling pain of an acute muscle spasm — the wrenched back, the seized neck, the strain or sprain that has locked a muscle into a painful contraction — and needs faster relief than an oral tablet can give. What makes orphenadrine distinctive is its mix of actions: it is a centrally acting muscle relaxant, structurally related to the antihistamine diphenhydramine, that also carries anticholinergic and mild local-anaesthetic and analgesic properties, so it eases muscle pain through more than one route. Given by intramuscular or intravenous injection it acts quickly, which is why it is valued as an adjunct to rest, physiotherapy and other measures in the early, most painful phase of a musculoskeletal injury. Because the injection is given to patients in acute pain, the dose delivered from each unit must be exact, sterile, particulate-free and reliably the same from unit to unit, since the prescriber depends on a precise, ready, reproducible parenteral dose.
That clinical reality places real demands on the manufacturer. Orphenadrine Citrate Injection is an aqueous solution — typically 30 mg of orphenadrine citrate per millilitre, presented for example as 60 mg in a 2 mL ampoule — so the assay must be exact and the fill volume accurate so each unit delivers the labelled content. The solution is compounded at a controlled pH that keeps orphenadrine citrate stable, often with an antioxidant such as sodium metabisulfite to protect it, and it must stay clear and colourless and free of visible and sub-visible particulates and low in endotoxin. Where a sulfite antioxidant is used, its level must be controlled and declared, and the anticholinergic cautions — the contraindications in conditions such as glaucoma, prostatic enlargement with urinary retention, pyloric or duodenal obstruction and myasthenia gravis, and the danger of overdose — clearly carried on the label. The right sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — must be selected and validated. Choosing an Orphenadrine Citrate Injection manufacturer that treats the stability-indicating assay, related-substance and pH control, antioxidant and sulfite control, fill-volume accuracy, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Orphenadrine Citrate Injection Manufacturer Apart
A world-class manufacturer of Orphenadrine Citrate Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of orphenadrine citrate with related-substance control by validated HPLC that an anticholinergic muscle relaxant with a real overdose risk demands, a robust, validated sterilisation and fill process that protects sterility, clarity, pH and — where a sulfite antioxidant is used — the antioxidant level on which solution stability depends, and tender-ready dossier support for a high-volume emergency and orthopaedic product procured through hospital-pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade orphenadrine citrate sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay, the clarity and the pH of the solution. The bulk solution is compounded in water-for-injection at the controlled pH that keeps orphenadrine citrate stable, with antioxidant protection and nitrogen purging where the formulation calls for it, then sterile-filtered through 0.22 µm membrane and filled into ampoules or vials under ISO Class 5 conditions, with the validated sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of orphenadrine citrate by validated HPLC, the related-substance profile, solution pH, antioxidant content where used, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intramuscular and intravenous administration. Because orphenadrine has a meaningful anticholinergic action and a real overdose risk, assay accuracy, content uniformity, related-substance control and container-closure integrity are validated together so the assay and clarity stay within specification across shelf life.
Quality Systems Behind Every Orphenadrine Citrate Injection
Every Farbe Firma Orphenadrine Citrate Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of orphenadrine citrate against pharmacopoeial reference standards, control of related substances by HPLC, solution pH, antioxidant content where a sulfite is used, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule or vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because orphenadrine citrate injection is an anticholinergic muscle relaxant given parenterally and the assay, content uniformity, related-substance profile, pH, antioxidant level, particulate and endotoxin burden drive both efficacy and safety, we treat the stability-indicating assay, the related-substance profile, the solution pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, so the assay, clarity and pH stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Orphenadrine Citrate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad emergency, orthopaedic and musculoskeletal small-volume parenteral portfolio. For Orphenadrine Citrate Injection specifically, we supply the 30 mg/mL solution in ampoule and vial presentations under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, related-substance, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability packages, stability-indicating method-validation data, sterilisation and container-closure reports, translated package inserts and artwork — including intramuscular and intravenous route instructions and the anticholinergic contraindications and overdose cautions — for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Orphenadrine Citrate Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance control, controlled-pH and antioxidant formulation design, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For an anticholinergic muscle relaxant where assay accuracy and dose precision directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Orphenadrine Citrate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Orphenadrine Citrate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated compounding and ampoule and vial filling lines, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Orphenadrine Citrate Injection do you supply?
Our standard presentation is the 30 mg/mL solution of orphenadrine citrate in an ampoule or vial (for example 60 mg in 2 mL), given by intramuscular or intravenous injection. Custom strengths, fill configurations, ampoule and vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Orphenadrine Citrate Injection mainly used for?
Orphenadrine Citrate Injection is used for the short-term relief of pain from acute musculoskeletal conditions — such as a strained or spasming muscle — as an adjunct to rest, physiotherapy and other measures. It is a centrally acting muscle relaxant with anticholinergic and antihistaminic properties and acts quickly when given by injection; Farbe Firma verifies the assay, related-substance profile, pH, antioxidant level, deliverable volume, particulate matter and endotoxin at release so each unit delivers a precise, reproducible dose. Because of its anticholinergic action it is contraindicated in conditions such as glaucoma and urinary retention and is labelled accordingly.
Can Farbe Firma support country-specific registrations for Orphenadrine Citrate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability packages, stability-indicating method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Orphenadrine Citrate Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, label complexity and dossier requirements. For our emergency and orthopaedic small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments